Page 1

July 31 , 2026 fibrobiologics FibroBiologics Reports Second Quarter 2026 Financial Results ; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026 HOUSTON , July 31 , 2026 / PRNewswire / -- FibroBiologics , Inc. ( Nasdaq : FBLG ) ( " FibroBiologics " ) , a clinical - stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast - derived materials , today reported financial results for the second quarter ended June 30 , 2026 , and provided a corporate update . fibrobiologics Recent Highlights : Clinical Updates : • Initiation of patient dosing in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers ( DFUS ) . • Financing : Completed manufacturing of three batches of the CYWC628 drug product in accordance with FDA's Good Manufacturing Practices ( cGMP ) . Two of these batches have been released and the third batch will be released after it successfully passes all required safety and quality testing . • Strengthened financial position through completion of a $ 9.0 million private placement with $ 3.0 million upfront and up to approximately $ 6.0 million of potential additional gross proceeds upon the exercise in full of warrants . Additionally , closed a $ 3.0 million public offering . Preclinical Progress : • Reported preclinical results suggesting that topical treatment with human dermal